[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adult-participants-with-elevated-lipoproteina\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adult-participants-with-elevated-lipoproteina":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100643631",false,"NCT07640217","A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a)","A Phase II Randomized, Double-Blind, Parallel-group, Placebo-Controlled Trial of SYH2068 Injection in Adults With Elevated Lipoprotein(a)","Inclusion Criteria:\n\n1. Male or female participants ≥18 years of age;\n2. Elevated Lp(a);\n3. Participants who have used lipid-lowering drugs continue to use a stable dose, and those who have not used do not start new lipid-lowering drugs;\n4. Presence of ASCVD or ASCVD risk stratification assessed as moderate or high risk;\n5. Participants are able to understand and cooperate to complete this study, voluntarily participate in this study, and sign the ICF.\n\nExclusion Criteria:\n\n1. Diseases that significantly affect Lp(a) during screening period,\n2. Major or unstable cardiovascular events occurring from 3 months before signing the ICF to randomization;\n3. Undergoing or expected to undergo peripheral arterial, coronary, or cerebrovascular revascularization surgery or other major surgery within 3 months prior to signing the ICF until randomization or during the study period;\n4. NYHA class III-IV at the time of signing the ICF or LVEF \\\u003C40% during the screening period;\n5. Type 1 diabetes or hereditary hemorrhagic disorder at screening;\n6. History of malignant tumor or suspected malignancy within 5 years prior to screening;\n7. Use of drugs affecting Lp(a) within the specified period before screening or expected to use during the study period;\n8. Allergy to oligonucleotide drugs;\n9. Received any other clinical study treatment within 3 months prior to screening or within 5 half-lives of the investigational drug;\n10. Female participants who are pregnant or breastfeeding at screening, or female \u002F male participants who plan to conceive during the study and within 1 year after the last dose.","ALL","18 Years",{"count":18,"type":19},120,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","The purpose of this study is to evaluate the efficacy and safety of SYH2068 injection in patients with elevated lipoprotein(a).",[25],"Adult Participants With Elevated Lipoprotein(a)","NOT_YET_RECRUITING","2026-06-05",{"date":29,"type":30},"2026-06-10","ACTUAL",{"date":32,"type":19},"2026-07-30",{"date":34,"type":19},"2028-09-30",{"name":36,"class":37},"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","INDUSTRY",""]